Oral liquids · Contract manufacturing in India

Bacillus Clausii 2 Billion Spores / 5 ml · Oral suspension

Request a quote from Walter Healthcare for third-party manufacturing of Bacillus Clausii 2 Billion Spores/5 mL oral suspension in India. Explore 10 × 5 mL packs, minimum orders and dispatch timing.

Catalogue reference
WH-1674
Composition and strength
Bacillus Clausii 2 Billion Spores / 5 ml
Dosage form
Oral suspension
Indicative administration route
Oral
Therapeutic navigation area
Other & specialty products
Pharmacological class
Specialty therapeutic agent
Manufacturing stream
Non-beta-lactam

How we pack and manufacture this product

Our pack history

10 × 5 mL pack

We’ve accepted ten 5 mL units in a pack. Give us your target number of retail packs and we’ll quote the primary containers and outer packaging.

Manufacturing for your brand

Oral suspension

Tell us your fill volume and the number of retail packs you need. We’ll check the formulation against the proposed unit’s product permission and confirm the pack components in your quote.

Review our manufacturing documents

We confirm the manufacturing site and commercial terms for your order at quotation.

Quality systems aligned with

GMPWHO-GMP Certified PlantsWHO-GDP compliantRevised Schedule MGLP · Schedule L-1FSSAIFacility-scoped evidence

Bacillus clausii contract manufacturing

Compare the single-ingredient presentations before requesting a quote. The catalogue lists the strength. The examples below show how Indian suppliers package each presentation for sale.

Oral suspension

2 billion spores per 5 mL

A listed carton holds 10 mini bottles of 5 mL each. Specify the fill per bottle, bottles per carton and number of cartons for your first order.

Two catalogue records list this strength. WH-1674 · this recordWH-5447

Pack example from Sherwell Biotech

Hard-gelatin capsule

2 billion spores per capsule

A listed retail pack contains one strip of 4 capsules. Specify capsules per strip, strips per carton and your order quantity. You can also request a bottle count for review.

Single-ingredient catalogue record. WH-4746

Indian retail strip example

Looking for the multi-ingredient DR capsule? WH-4747

Plan your first order

The target pack, initial quantity, artwork approval, production slot and quality release determine Walter’s dispatch date. As a market reference for the suspension, Livealth lists 45 days for its 10 × 5 mL presentation. Walter confirms its own pack availability, MOQ and schedule in the written quote. Supplier listing

Confirm the manufacturing site

Request the proposed unit’s name, manufacturing licence, permission for this composition and current GMP certificate scope. For supplier qualification, ask which product specifications and batch certificates of analysis are available. Walter’s facility documents

Request a suspension quote

Editorial development perspective

What deserves attention in this formulation.

These notes use the catalogue composition and presentation to frame a technical discussion. They are planning considerations, not tested properties or clinical findings for this product.

A matching clinical reference has not yet been verified for this page. Drug-specific mechanisms and human pharmacokinetic values remain open for review.

About these development notes and source limitations ↗

Review the suspension after standing

Listed presentation: Oral suspension.

Assess how the formulation settles, how readily it redistributes and whether a representative portion can be withdrawn with the proposed measuring device. Record particle-size and viscosity considerations where relevant. A freshly mixed appearance alone is a weak basis for selecting a suspension; repeat the assessment during the intended storage and use conditions.

Put organism identity and viability first

Catalogue wording: “Bacillus”.

Ask for the organism and strain identifiers, the method used to measure viable content, and whether the declared count applies at manufacture or through shelf life. In a mixture, clarify the amount assigned to each organism. Assess viability with the proposed process, accompanying ingredients and pack; a total count alone does not describe the complete formulation.

Translate the listed strength into a quantitative formula

Strength expressions in this entry include “2 Billion”.

Tie every stated ingredient amount to its intended dosage unit or measure, then distinguish that declared amount from the quantity of raw material needed for a batch. Record any assay or equivalence calculation in the formula. This gives development, purchasing and artwork teams the same strength definition without assigning a patient dose from the catalogue.

Suggested starting point

A practical starting point is to put organism identity and viability first. For this oral suspension brief, agree the target characteristics and a short set of measurable development questions before comparing prototypes or supplier proposals. Keep unresolved clinical claims outside the product specification until supporting evidence is available.

Discuss this product brief

Our clients

Trusted by companies building healthcare’s next generation.

Trusted manufacturing partner

Pharma, nutraceutical and fast-growing D2C companies choose Walter.

Manufacturing & packaging brief

Plan the oral-suspension presentation.

Use this preparation guide for Bacillus Clausii 2 Billion Spores / 5 ml Oral suspension. These are the decisions to resolve with the technical team before a site, process and commercial scope are confirmed.

Presentation & formulation

Clarify whether the requirement is a ready-to-use suspension or a powder for reconstitution. Provide concentration, final volume and formula details for the requested presentation.

Quality & technical transfer

Request review of the applicable suspension specification, analytical methods and measuring accuracy. Reconstitution and in-use statements need their own supporting evidence where relevant.

Review the technical documents

Packaging configuration

Specify bottle capacity, fill or reconstitution volume, closure and measuring device. List any diluent or accessory separately in the brief.

Explore packaging options

Details to confirm for this record

Concentration and pack size
The record includes a concentration or percentage expression. Confirm its complete basis, then specify the finished fill volume or weight separately. Do not treat pack size as the strength.

Quantities, MOQ & lead time

For Bacillus Clausii 2 Billion Spores / 5 ml Oral suspension, state the bottle count and finished volume, target market and reorder forecast. MOQ and lead time depend on the assessed formula, process, components, testing and project readiness; request those terms in writing.

Discuss this manufacturing brief

Explore the context

Build the right manufacturing brief.

Common questions

Before you request a quotation.

Bacillus Clausii 2 Billion Spores / 5 ml Oral suspension

What is listed in the catalogue?

The catalogue lists Bacillus Clausii 2 Billion Spores / 5 ml as oral suspension in its other & specialty products navigation area and non-beta-lactam manufacturing stream.

How do you confirm manufacturing availability?

Send Walter your requirement for Bacillus Clausii 2 Billion Spores / 5 ml Oral suspension. The team reviews the applicable product permission and unit, formulation and equipment fit, testing, packaging and production schedule before confirming the manufacturing scope in writing. Request the relevant product and facility documents with your enquiry.

What do I need for a quotation?

Share the exact composition and strength, oral suspension presentation, target market, initial quantity, preferred pack and timing. Identify whether this is a new product, development brief or transfer.

The quotation must confirm MOQ, inclusions, prerequisites and lead time for the proposed product and site.

What is needed for Indian and export markets?

For India, share the intended brand or institutional supply requirement, pack sizes, initial order quantity and artwork needs for Bacillus Clausii 2 Billion Spores / 5 ml Oral suspension. Confirm the applicable product permission, manufacturing unit and labelling requirements with the team.

For export, identify each destination country, proposed pack, language and registration or dossier requirements. Ask which product-specific quality and stability documents are available. Container compatibility and destination-market requirements need review; a catalogue record does not establish export registration or a shelf-life commitment.

How do I submit my enquiry?

Use the product-specific enquiry button to carry this composition and dosage form into the form. After a successful submission, a receipt reference confirms that your brief has been saved for review. Use the RFQ checklist to prepare the remaining details.

Technical document review

Which documents can I ask Walter to review?

Ask about manufacturing and packing records, specifications, analytical methods, Certificates of Analysis (COA), stability evidence, the Process Validation Protocol (PVP) and Process Validation Report (PVR). The wider checklist below covers supplier qualification, technical transfer and ongoing supply.

View the full document checklist 14 review areas
Site, licence and audit scope
Manufacturing licence, applicable product permissions, GMP certificates, Site Master File, supplier-qualification questionnaire and relevant audit responses.
Manufacturing, packing and batch release
Master Formula Record (MFR), master packing instructions, Batch Manufacturing Record (BMR), Batch Packing Record (BPR), reconciliation and authorised release records.
Process validation and continued verification
Process Validation Protocol (PVP), Process Validation Report (PVR), process performance qualification documents and continued process verification trends.
Equipment, facilities and utilities
Validation Master Plan (VMP), user requirements, DQ/IQ/OQ/PQ records, calibration and maintenance evidence for relevant equipment and utilities.
Cleaning, carryover and hold times
Cleaning Validation Protocol (CVP), Cleaning Validation Report (CVR), residue limits, recovery studies and applicable clean, dirty and process hold-time studies.
Specifications and analytical evidence
Specifications, Method of Analysis (MOA), Standard Testing Procedure (STP), Certificates of Analysis (COA), analytical validation, verification and method-transfer records.
Stability, packaging and transport
Stability protocols/reports, ongoing stability commitments, pack specifications, approved artwork, compatibility and applicable packaging or transport studies.
Development and technology transfer
Development report, technology-transfer protocol/report, gap assessment, control strategy, critical quality attributes and critical process parameters.
Quality reviews, investigations and changes
Product Quality Review (PQR) / Annual Product Review (APR), deviations, CAPA, change control, OOS/OOT trends, complaints, recalls and relevant SOP/training records.
Material suppliers and impurity risks
API/excipient supplier qualification, traceability, material COAs, relevant origin declarations and impurity risk assessments with supporting tests.
Sterile-product evidence, where applicable
Contamination Control Strategy (CCS), media-fill/aseptic simulation reports, sterilisation and filtration validation, environmental monitoring, sterility/endotoxin and container-closure integrity evidence.
Computerised systems and data integrity
Computerised-system validation, access controls, audit-trail review, backup/restore checks and relevant data-integrity procedures.
Market-specific regulatory support
Applicable dossier sections, API master-file/CEP support, bioequivalence or biowaiver evidence and Certificate of a Pharmaceutical Product (CPP/CoPP), where required and available.
Quality agreement and access arrangements
Quality/technical agreement covering responsibilities, release, changes, subcontracting, investigations, complaints, recalls, audits and document access.

Agree the list for the exact product, site, process, pack, market and project stage. QA confirms what exists, applies and may be shared; some records may require an NDA, redaction or controlled review. See document definitions and review guidance.

Important qualification

This B2B catalogue record is not proof of current approval or confirmation that Bacillus Clausii 2 Billion Spores / 5 ml Oral suspension is available for sale. It is not prescribing information or patient advice. Any Drugs Rules status, current approval, exemption, applicable unit, licence scope, formulation, claims, brand use, destination-market registration and commercial feasibility require documentary verification and Walter's written confirmation. Read the full regulatory disclaimer.

Composition and classification are taken from Walter's product catalogue. The manufacturing guide helps buyers prepare a technical brief. Clinical references, where shown, describe the cited product and study. Product page updated .

Quick chat on WhatsAppLet’s discuss your product